Many GLP-1 Drug Problems

GLP-1 Drug Problems and How Often They Occur (2026)

The most common problem with GLP-1 drugs is gastrointestinal (GI) upset: about 3 in 4 people on semaglutide 2.4 mg report GI symptoms, compared with about half on placebo.[1][2] Serious problems are much rarer. Gallbladder disease, pancreatitis, retinopathy worsening and NAION each affect from under 1% to a few percent of users, or fewer than 1 in 10,000 for NAION. The biggest practical problems are tolerability, lean-mass loss and weight regain after stopping.

TL;DR

  • Common and expected: In the Wegovy label, 73% of semaglutide 2.4 mg users had GI adverse reactions vs 47% on placebo (nausea 44% vs 16%).[1][2] Tirzepatide's rate is similar (56% vs 30%).[3][4][5] These symptoms drive treatment discontinuation of about 6–17% on drug vs 3–8% on placebo.[2][6][7][8][9]
  • Real but uncommon serious risks: These include gallbladder disease (RR 1.37 across 76 RCTs), worsening of existing diabetic retinopathy (3.0% vs 1.8% in SUSTAIN-6)[10][11][12] and NAION (rated "very rare", ≤1 in 10,000, by EMA).[13] Pancreatitis, gastroparesis and bowel obstruction show signals only in observational studies, and randomized trials don't show a clear excess.[14][15]
  • Signals that have mostly been reassured away: Suicidality was cleared after FDA's 91-trial analysis.[16][17] Human thyroid cancer data are mixed but mostly null (HR 0.93 in a Scandinavian cohort).[18] Aspiration under anesthesia remains debated because retained gastric content clearly rises but aspiration events don't consistently increase.[19][20][21]

Key Findings

  • Tolerability is the real-world limiting factor. GI events cluster during dose escalation and are dose-dependent.[5][22] Triple and amylin combinations are at least as GI-heavy: CagriSema caused nausea in 55% of users, and retatrutide 12 mg caused nausea in about 42–43%.[23][24][25][26]
  • Most "serious" risks have small absolute effects. For gallbladder disease, He and colleagues' 2022 JAMA Internal Medicine meta-analysis (76 RCTs, 103,371 patients) reported "an additional 27 cases per 10,000 persons treated per year." For NAION, the EMA's safety committee (PRAC) said in June 2025 that this "corresponds to approximately one additional case of NAION per 10,000 person-years of treatment."
  • Quality of weight loss and what happens afterwards matter as much as side effects. About 25% of weight lost on tirzepatide was lean mass in the SURMOUNT-1 DXA substudy ("about 75% of the weight lost was fat and 25% was lean mass"), versus a reported 38–45% for semaglutide in STEP 1. In the STEP 1 extension (Wilding et al., Diabetes Obes Metab 2022, n=327), "participants regained two-thirds of their prior weight loss" within a year of stopping semaglutide.
  • A new agent-specific signal is dysesthesia (abnormal skin sensation) with retatrutide. It affected up to 20.9% of users at 12 mg in TRIUMPH-4, vs 0.7% on placebo.[25][27]

Table 1. Common problems (gastrointestinal and tolerability)

Problem Incidence on drug Incidence placebo Relative risk / notes Drug(s) studied Refs
Any GI adverse reaction 73% 47% Severe GI 4.1% vs 0.9%[1][2] Semaglutide 2.4 mg Wegovy label 2026
Wegovy label 2025
Any GI adverse reaction 56% at each dose 30% Mostly during dose escalation[3][4][5] Tirzepatide 5–15 mg Zepbound label
Nausea 44% 16% About 2.8× placebo; mostly mild to moderate[1][2][5] Semaglutide 2.4 mg Wegovy label 2025
Nausea ≈24–33% ≈8–10% Dose-related[28][29][30] Tirzepatide 5–15 mg Zepbound label
SURMOUNT-1 summary
Vomiting 25% 6% About 4× placebo[1][2] Semaglutide 2.4 mg Wegovy label 2025
Diarrhea 30% 16% About 2× placebo[1][2] Semaglutide 2.4 mg Wegovy label 2025
Constipation 23.4% 9.5% STEP 1, 68 weeks[31] Semaglutide 2.4 mg STEP 1 CT.gov
Dyspepsia 10.3% 3.5% Eructation 8.6% vs 0.5%[31] Semaglutide 2.4 mg STEP 1 CT.gov
GERD 9.9% 4.0% STEP 5, 104 weeks[32] Semaglutide 2.4 mg STEP 5 CT.gov
Abdominal pain 13.0% 4.9% STEP 3 Semaglutide 2.4 mg STEP 3 CT.gov
Discontinuation due to AEs 6.8% 3.2% Mainly nausea 1.8% and vomiting 1.2%[2][6] Semaglutide 2.4 mg Wegovy DailyMed
Discontinuation due to AEs 16.6% 8.2% SELECT, 3.3-year median; GI 10.0% vs 2.0%[15][33][34] Semaglutide 2.4 mg SELECT safety
TCTMD SELECT
Discontinuation due to AEs 4–10.5% 2.1–4% Across SURMOUNT trials[35] Tirzepatide Tirzepatide review
Injection-site reactions 6–8% 2% More frequent with anti-drug antibodies[28][36] Tirzepatide Zepbound label 2026
Hair loss (alopecia) 3.3% 1% Women 4% vs men 0.9%; 5.8% at 7.2 mg[2][37] Semaglutide 2.4 mg Wegovy label 2026
Hair loss (alopecia) ≈4–5% ≈1% Listed among ≥5% reactions[28][36][38][39] Tirzepatide Zepbound label
Hypotension 1.3% 0.4% Syncope 0.8% vs 0.2%[2][6][40] Semaglutide 2.4 mg Wegovy DailyMed
Hypotension 1.6% 0.1% Volume loss from GI events[41] Tirzepatide Zepbound FDA SPL
Increased heart rate +1 to 4 bpm mean Not reported Adolescents: ≥20 bpm rise in 54% vs 39%[2][6][40][42] Semaglutide 2.4 mg Wegovy label 2026

Table 2. Serious, rare or debated problems

Problem Incidence on drug Incidence on placebo Relative risk / notes Drug(s) studied Refs
Gallbladder/biliary disease RR 1.37 overall Placebo or active RR 2.29 in weight-loss trials; 27 extra cases per 10,000 per year (He, JAMA IM 2022); meta-analysis of 76 RCTs GLP-1 RA class He JAMA IM 2022
Gallbladder review
Gallbladder disorders 2.8% 2.3% p=0.04; cholelithiasis 1.4% vs 1.1%[43] Semaglutide 2.4 mg SELECT safety
Cholecystitis 0.7% 0.2% Cholelithiasis 1.1% vs 1%; cholecystectomy 0.2% vs 0%[41][44] Tirzepatide Zepbound label
Acute pancreatitis (RCT) 0.2% 0.3% No excess in SELECT[9][15] Semaglutide 2.4 mg NERDCAT SELECT
Acute pancreatitis (observational) 4.6–7.9 per 1,000 PY 1.0 per 1,000 PY HR 9.09 (95% CI 1.25–66.0); very imprecise[45][46] Semaglutide, liraglutide vs bupropion-naltrexone TCTMD Sodhi
Endocrinology Advisor
Gastroparesis 7.3–9.1 per 1,000 PY 3.1 per 1,000 PY HR 3.67 (1.15–11.9); observational[45][46] Semaglutide, liraglutide TCTMD Sodhi
Bowel obstruction 0–8.1 per 1,000 PY 1.7 per 1,000 PY HR 4.22 (1.02–17.4); observational[45] Semaglutide, liraglutide Endocrinology Advisor
Retained gastric content at anesthesia OR 5.96 vs non-users Non-users Low-certainty evidence; holding ≥1 dose gave OR 0.51[20][47] GLP-1 RA class Elkin Anaesthesia 2025
Pulmonary aspiration Conflicting Non-users Endoscopy meta-analysis OR 2.29 (1.36–3.87); another OR 1.23, not significant[19][48] GLP-1 RA class Endoscopy meta 2025
Endoscopy meta 2
Hypoglycemia with sulfonylurea Severe 0.8–1.2% Not reported Documented symptomatic 17.3–24.4%[12][49] Semaglutide 0.5–1 mg Ozempic label 2026
Hypoglycemia with insulin Severe 0–1.5%; <54 mg/dL 13–19% Severe 0%; <54 mg/dL 13% SURPASS-5 and SUSTAIN-5[12][50] Tirzepatide, semaglutide Mounjaro label
Ozempic label 2026
Hypoglycemia, T2D on weight dose 6.2% (<54 mg/dL) 2.5% Higher risk with sulfonylurea[2] Semaglutide 2.4 mg Wegovy label 2026
Acute kidney injury Not increased Similar SELECT showed no AKI excess; label warns about dehydration[2][9][34] Semaglutide 2.4 mg Cleveland Clinic SELECT
Diabetic retinopathy complications 3.0% 1.8% HR 1.76 (1.11–2.78); 84% had pre-existing DR[10][51] Semaglutide 0.5–1 mg SUSTAIN-6 NEJM
Diabetic retinopathy (meta-analysis) RR 1.20 Comparators 95% CI 0.99–1.47; borderline[52] Semaglutide AAO statement
NAION ≤1 per 10,000 users Not reported EMA "very rare"; observational studies about 2× risk[13][53] Semaglutide WHO alert
AAO NAION 2026
NAION (RCT pool) 15 probable events 134,253 participants FDA required a class-wide warning in Nov 2026[54] All GLP-1 RAs Pharmacally FDA
Thyroid cancer, all types HR 0.93 DPP-4 inhibitor users 95% CI 0.66–1.31; Scandinavian cohort of 145,410[18][55] Liraglutide, semaglutide Pasternak BMJ 2024
Medullary thyroid cancer HR 1.19 DPP-4 inhibitor users CI 0.37–3.86; French study HR 1.78 (1.04–3.05)[18][56] GLP-1 RA class Pasternak BMJ 2024
Suicidal ideation/behavior No increase Placebo FDA analysis of 91 RCTs (n=107,910); warning removal requested[16][17] Liraglutide, semaglutide, tirzepatide Pharmacy Times FDA
HCPLive FDA
Suicidality (observational) RR 0.57 Other antidiabetics 95% CI 0.08–4.21; not significant[57] GLP-1 RA class Padhi meta 2025
Hypersensitivity 5% 3% Severe 0.1% vs 0%; anaphylaxis seen postmarketing[28][36] Tirzepatide Zepbound label
Lean mass loss ≈38–45% of weight lost Not reported Lean mass −9.7% (Wilding, STEP 1 DXA); share reported variously as 38%, 39.7% or 45% Semaglutide 2.4 mg Healio lean mass
DDT lean mass
Lean mass loss ≈25% of weight lost ≈25% on placebo Lean mass −10.9%,[58] fat −33.9% (SURMOUNT-1 DXA, n=160) Tirzepatide Healio lean mass
Bone density loss Not quantified Not reported Human data largely neutral[59] GLP-1 RA class BMD pilot trial
Nutritional deficiency 12.7% at 6 mo; 22.4% at 12 mo Metformin-only users lower Vitamin D deficiency 7.5% then 13.6%; claims data, n=461,382[60][61] GLP-1 RA class Butsch Obesity Pillars
Weight regain after stopping ≈2/3 of lost weight in 1 year Placebo regained 1.9 points Regained 11.6 of 17.3 percentage points[62][63] (Wilding, STEP 1 extension, n=327) Semaglutide 2.4 mg STEP 1 extension
Weight regain after stopping +14.0% body weight −5.5% if continued SURMOUNT-4, 52 weeks[64] Tirzepatide Weight regain review
Compounded dosing errors 5–20× intended dose Not reported Some cases hospitalized; mg-to-units confusion[65][66][67] Compounded semaglutide FDA alert 2024
Poison center exposures 22,966 cases, 2019–2025[68] Not reported ≈1,500% rise in calls since 2019[68][69] GLP-1 RA class America's Poison Centers
"Ozempic face" / skin laxity Not quantified Not reported Consequence of rapid fat loss; no trial incidence GLP-1 RA class Not reported

Table 3. Newer agents (phase 3 data)

Problem Incidence on drug Incidence placebo Relative risk / notes Drug(s) studied Refs
Nausea 28.6% / 38.4% / 42.4% 14.8% TRIUMPH-1 at 4/9/12 mg[23][24] Retatrutide Lilly TRIUMPH-1
AJMC TRIUMPH-1
Dysesthesia 5.1% / 12.3% / 12.5% 0.9% TRIUMPH-4 at 12 mg: 20.9% vs 0.7%[23][25] Retatrutide Lilly TRIUMPH-1
Retatrutide safety
Discontinuation due to AEs 4.1% / 6.9% / 11.3% 4.9% TRIUMPH-4 at 12 mg: 18.2% vs 4.0%[24][25] Retatrutide AJMC TRIUMPH-1
Nausea 33.7% at 36 mg ≈12% ATTAIN-1 Orforglipron GI review PMC
Discontinuation due to AEs 5.3–10.3% 2.7% 5 mild pancreatitis cases, all on drug[7][70] Orforglipron ATTAIN-1 NEJM
Diabetes Distilled
Any GI adverse event 79.6% 39.9% Nausea 55% vs 12.6%; vomiting 26.1% vs 4.1%[26][71] CagriSema Novo REDEFINE 1
Discontinuation due to AEs 5.9% 3.5% REDEFINE 2: 8.4% vs 3%[72][73] CagriSema Novo FDA filing

Caveats

  • Trial rates vs real-world rates: Trials use slow dose escalation and exclude high-risk patients. Real-world GI rates and discontinuation are likely higher. In SELECT, discontinuation over 3+ years was more than double the 68-week label figure.[2][8]
  • Observational signals are imprecise: The pancreatitis HR of 9.09 has a 95% CI of 1.25–66.0.[74] The Sodhi cohort had only 613 semaglutide users and an active comparator (bupropion-naltrexone),[14] which may itself lower GI risk. Large RCTs such as SELECT found no pancreatitis excess (0.2% vs 0.3%).[15]
  • NAION: The FDA class-wide warning (Nov 2026) is reported here through a trade-press summary, not the FDA document itself.[54] Within the RCT data, the evidence rests on very few events.[54]
  • Lean mass is not the same as muscle: DXA "lean mass" includes water and organs. In SURMOUNT-1, the lean share of weight lost was similar on placebo, which suggests this is largely a weight-loss effect rather than a drug-specific one.[58][75]
  • Nutritional deficiency data: These come from claims coding. Patients who saw a dietitian were diagnosed more often, so detection bias is likely, and causality is not established.[61][76][77]
  • Gaps: Drug-specific incidence for liraglutide, dulaglutide and exenatide was not separately tabulated here. Their GI profile is broadly similar to the class, and liraglutide appears in the Sodhi cohort.[14] No validated incidence exists for "Ozempic face" or for bone loss.

Recommendations

  • Expect and manage GI effects: escalate doses slowly and eat smaller meals.[78] Treat persistent severe vomiting as a dehydration and kidney risk.[2]
  • Before starting, check retinal status in people with diabetes and existing retinopathy. Lower sulfonylurea or insulin doses to avoid hypoglycemia.[12][79]
  • Protect lean mass with resistance training and adequate protein.[80] Consider vitamin D and micronutrient checks at 6–12 months.[61]
  • Before procedures with sedation, tell the anesthetist or endoscopist about GLP-1 use.[2] Holding at least one dose or following a liquid diet reduces retained gastric content.[20][81]
  • Plan for long-term use or a structured exit, because stopping typically reverses about two-thirds of the weight lost within a year.[62]
  • Avoid compounded products when possible. If you use them, confirm the dose in both mg and units with the pharmacist, because 5–20× overdoses have been reported.[67][68]
Sources:

Sources

  1. HIGHLIGHTS OF PRESCRIBING INFORMATION
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION
  3. Highlights of Prescribing Information - accessdata.fda.gov
  4. Zepbound Injection, Solution - FDA Label NDC 0002-2471
  5. GLP-1 Side Effects by Week: What's Normal, What's Not
  6. Label: Wegovy- semaglutide injection, solution - DailyMed - NIH
  7. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
  8. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial - PubMed
  9. International Clinical Trial Finds that Semaglutide Reduced Cardiovascular Events by 20% in Adults with Overweight or Obesity Who Don’t Have Diabetes
  10. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
  11. GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
  12. highlights of prescribing information - accessdata.fda.gov
  13. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)
  14. GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
  15. SELECT: Semaglutide in patients with CV disease & overweight/obesity — NERDCAT
  16. FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Removal of Warning Labels
  17. FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies
  18. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
  19. Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis - PubMed
  20. Association between glucagon‐like peptide‐1 receptor agonist use and peri‐operative pulmonary aspiration: a systematic review and meta‐analysis - Elkin - 2025 - Anaesthesia - Wiley Online Library
  21. Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis
  22. Tirzepatide Side Effects: Nausea, Diarrhea, Rates by Dose & Management (2026)
  23. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
  24. Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
  25. Retatrutide Side Effects and Safety: What the Phase 3 Data Actually Shows (2026)
  26. Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
  27. Retatrutide Side Effects: Phase 3 Trial Data
  28. Zepbound Side Effects: Full Breakdown by Frequency
  29. Tirzepatide before and after: what the trials actually show
  30. SURMOUNT-1 Trial Results: Tirzepatide Weight Loss Study Explained
  31. STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
  32. Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
  33. Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics
  34. First study with positive cardiovascular outcome in obesity: Reflections on SELECT
  35. Full article: Tirzepatide for overweight and obesity management
  36. These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND® (tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
  37. Do GLP-1s Cause Hair Loss? FDA Label Rates
  38. GLP-1 Hair Loss: Why It Happens and How Long It Lasts
  39. Tirzepatide and Semaglutide Hair Loss
  40. Wegovy: Package Insert / Prescribing Information / MOA
  41. These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.<br/>ZEPBOUND™ (tirzepatide) Injection, for subcutaneous use<br/>Initial U.S. Approval: 2022
  42. HIGHLIGHTS OF PRESCRIBING INFORMATION These ...
  43. "Safety profile of semaglutide versus placebo in the SELECT study: a ra" by Robert F. Kushner, Donna H. Ryan et al.
  44. ZEPBOUND (tirzepatide) injection - accessdata.fda.gov
  45. GLP-1 Agonist Use for Weight Loss Linked to Gastrointestinal Adverse Events - Endocrinology Advisor
  46. Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs
  47. Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis
  48. GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis
  49. DailyMed - OZEMPIC- semaglutide injection, solution
  50. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s031lbl.pdf
  51. SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes
  52. Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Retinopathy: A Statement from the American Academy of Ophthalmology - American Academy of Ophthalmology
  53. Glucagon-Like Peptide-1 Receptor Agonists
  54. FDA Requires Class-Wide NAION Warning for GLP-1 Drugs - Pharmacally
  55. Understanding the Ozempic Thyroid Cancer Warning and What It Means for Patients
  56. Semaglutide and Thyroid: What to Know
  57. Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis - PMC
  58. GLP-1 Muscle Loss: How Much Is Muscle and How to Measure It
  59. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis
  60. What Nutrients Are GLP-1 Users Lacking?
  61. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study - ScienceDirect
  62. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
  63. Weight Regain After Stopping a GLP-1: What the Studies Show
  64. Stopping a GLP-1 medicine: how much weight comes back in the STEP 1 extension and SURMOUNT-4 trials
  65. Compounded Semaglutide Side Effects: What to Expect
  66. GLP-1 Overdose: Dosing Errors and FDA Alerts
  67. FDA alerts health care providers, compounders of dosing errors
  68. Glucagon-like Peptide-1 (GLP-1) Agonists
  69. America's Poison Centers - Track Emerging Hazards
  70. Diabetes Distilled: New oral GLP-1 RA, orforglipron, achieves up to 11.2% mean weight loss - DiabetesontheNet
  71. What Is CagriSema? Trial Results, Muscle Data & Safety
  72. News Details
  73. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
  74. GLP-1 Gastroparesis Risk 2026: Causes, Prevention & When to Worry
  75. GLP-1 Muscle Preservation Protocol: Fighting Lean Mass Loss
  76. GLP-1 Agonists Linked to Increased Nutritional Deficiencies, Reveals Research
  77. GLP-1 Nutritional Deficiencies: What Research Shows
  78. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
  79. Label: OZEMPIC- semaglutide injection, solution - DailyMed
  80. Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
  81. The role of GLP-1 agonists in perioperative care: a suspension dilemma

Related in VitaminDWiki

Weight Loss and Vitamin D, etc,

Click on a tag to see studies: GLP-1 (15) Weight Loss (45)